Sputum bacterial density (CFU/mL) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.97 [0.89, 1.07]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.93 [0.77, 1.11]
Studies not reported
Low
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.94 [0.12, 70.67]
Studies not reported
Low
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Moderate
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1.12 [0.97, 1.29]
Studies not reported
Low
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1 [0.8, 1.27]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.66 [1.07, 6.59]
Studies not reported
Low
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Cramp frequency (percentage change from baseline at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp frequency (percentage change from baseline at 4 weeks) (moderate certainty).
1 finding from 1 review
Intervention not reported
Cramp frequency (responder analysis: 25% or better reduction at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp frequency (responder analysis: 25% or better reduction at 4… (high certainty).
1 finding from 1 review
Intervention not reported
Cramp frequency (mean number of cramps per week on treatment at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp frequency (mean number of cramps per week on treatment at 4… (moderate certainty).
1 finding from 1 review
Intervention not reported
Cramp intensity (moderate or worse at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp intensity (moderate or worse at 4 weeks) (moderate certainty).
1 finding from 1 review
Intervention not reported
Cramp duration (≥ 1 minute at 4 weeks) · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in cramp duration (≥ 1 minute at 4 weeks) (low certainty).
1 finding from 1 review
Intervention not reported
Major adverse events · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
It is very uncertain whether the intervention changes major adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Minor adverse events · for effects on cramps, people (other than pregnant women) with muscle cramps (largely older adults); for adverse events, all populations
The intervention showed no clear difference in minor adverse events (low certainty).
1 finding from 1 review
Mean consumption (purchased quantities) of taxed sugar‐added foods · general population
1 finding from 1 review
Mean expenditure on untaxed sugar‐added foods · general population
1 finding from 1 review